JP2011515672A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515672A5
JP2011515672A5 JP2011500224A JP2011500224A JP2011515672A5 JP 2011515672 A5 JP2011515672 A5 JP 2011515672A5 JP 2011500224 A JP2011500224 A JP 2011500224A JP 2011500224 A JP2011500224 A JP 2011500224A JP 2011515672 A5 JP2011515672 A5 JP 2011515672A5
Authority
JP
Japan
Prior art keywords
marker
markers
polypeptide marker
polypeptide
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011500224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515672A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/053242 external-priority patent/WO2009115570A2/de
Publication of JP2011515672A publication Critical patent/JP2011515672A/ja
Publication of JP2011515672A5 publication Critical patent/JP2011515672A5/ja
Pending legal-status Critical Current

Links

JP2011500224A 2008-03-19 2009-03-19 腎尿細管の損傷および疾患の診断のための方法およびマーカー Pending JP2011515672A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08153007.3 2008-03-19
EP08153007 2008-03-19
EP08167429 2008-10-23
EP08167429.3 2008-10-23
PCT/EP2009/053242 WO2009115570A2 (de) 2008-03-19 2009-03-19 Verfahren und marker zur diagnose von tubulären nierenschäden und -erkrankungen

Publications (2)

Publication Number Publication Date
JP2011515672A JP2011515672A (ja) 2011-05-19
JP2011515672A5 true JP2011515672A5 (enExample) 2012-05-17

Family

ID=40671165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011500224A Pending JP2011515672A (ja) 2008-03-19 2009-03-19 腎尿細管の損傷および疾患の診断のための方法およびマーカー

Country Status (4)

Country Link
US (1) US20120037507A9 (enExample)
EP (1) EP2255203A2 (enExample)
JP (1) JP2011515672A (enExample)
WO (1) WO2009115570A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
CA2680198C (en) * 2007-03-07 2016-01-19 Mosaiques Diagnostics And Therapeutics Ag Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
CA2701571A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide markers for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
WO2010031822A1 (de) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Nierenzellkarzinom
EP2449385A1 (de) * 2009-07-02 2012-05-09 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose eines akuten nierenversagens
EP2579033A4 (en) * 2010-05-31 2013-11-20 Noriaki Tanaka METHOD FOR DETERMINING THE PHASE OF A CHRONIC KIDNEY DISEASE, DEVICE THEREFOR AND OPERATING PROCESS FOR THE DEVICE

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
US6677114B1 (en) * 1999-04-20 2004-01-13 Target Discovery, Inc. Polypeptide fingerprinting methods and bioinformatics database system
DE10021737C2 (de) * 2000-05-04 2002-10-17 Hermann Haller Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
AU2001293699A1 (en) * 2000-07-12 2002-01-21 Werner Naser Direct assessment of analyte to reference molecule ratios
US20030003588A1 (en) * 2001-06-28 2003-01-02 Comper Wayne D. Method for kidney disease detection by protein profiling
DE10304106A1 (de) * 2003-01-31 2004-08-26 Mosaiques Diagnostics And Therapeutics Ag Verfahren und Vorrichtung zur qualitativen und/oder quantitativen Bestimmung eines Protein- und/oder Peptidmusters einer Flüssigkeitsprobe, die dem menschlichen oder tierischen Körper entnommen wird
US7425700B2 (en) * 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
DE10341193A1 (de) * 2003-09-06 2005-03-31 Mosaiques Diagnostics And Therapeutics Ag Vorrichtung und Verfahren zur quantitativen Auswertung der in einer Körperflüssigkeitsprobe enthaltenden Polypeptide sowie Marker zur Erkennung von pathologischen Zuständen
US20050244973A1 (en) * 2004-04-29 2005-11-03 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
US20060286602A1 (en) * 2004-05-10 2006-12-21 Harald Mischak Method and markers for the diagnosis of renal diseases
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
EP1866648A2 (de) * 2005-04-07 2007-12-19 mosaiques diagnostics and therapeutics AG Polypeptidmarker zur diagnose von prostatakrebs
EP1757939A1 (de) * 2005-08-26 2007-02-28 mosaiques diagnostics and therapeutics AG Polypeptidmarker zur Diagnose von Blasenkrebs
US20100062537A1 (en) * 2005-11-30 2010-03-11 Harald Mischak Polypeptide Markers for the Diagnosis and Evaluation of Pelvi-Ureteric Junction Obstruction (PUJO)
EP1977250A1 (en) * 2006-01-20 2008-10-08 mosaiques diagnostics and therapeutics AG Method and markers for the diagnosis of renal diseases
CA2680198C (en) * 2007-03-07 2016-01-19 Mosaiques Diagnostics And Therapeutics Ag Process for normalizing the concentration of analytes in a urine sample
EP1972940A1 (de) * 2007-03-14 2008-09-24 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Nierenerkrankungen
CA2701571A1 (en) * 2007-10-09 2009-04-16 Mosaiques Diagnostics And Therapeutics Ag Polypeptide markers for the diagnosis of prostate cancer
EP2051078A1 (de) * 2007-10-19 2009-04-22 mosaiques diagnostics and therapeutics AG Verfahren und Marker zur Diagnose von Diabetes Mellitus
WO2010031822A1 (de) * 2008-09-17 2010-03-25 Mosaiques Diagnostics And Therapeutics Ag Nierenzellkarzinom
WO2010079076A2 (de) * 2008-12-17 2010-07-15 Mosaiques Diagnostics And Therapeutics Ag Autosomal dominante polyzystische nierenerkrankung (adpkd)
EP2449385A1 (de) * 2009-07-02 2012-05-09 Mosaiques Diagnostics And Therapeutics AG Verfahren und marker zur diagnose eines akuten nierenversagens
WO2011029954A2 (de) * 2009-09-14 2011-03-17 Mosaiques Diagnostics And Therapeutics Ag Polypeptidmarker zur diagnostik und beurteilung vaskulärer erkrankungen

Similar Documents

Publication Publication Date Title
Gould et al. Breath analysis for detection of viral infection, the current position of the field
JP2017106933A5 (enExample)
JP2015503917A5 (enExample)
JP2016105097A5 (enExample)
van Dijk et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach
WO2012017466A8 (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
JP2012249614A5 (enExample)
WO2007117444A3 (en) Protein detection by aptamers
RU2014123987A (ru) Анализ адромедуллина и способы определения зрелого адромедуллина
JP2019524884A5 (enExample)
JP2014144959A5 (enExample)
JP2010207229A5 (enExample)
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
WO2015014794A8 (en) Use of alpha-crystallin b (cryab) in the assessment of heart failure
JP2015521728A5 (enExample)
WO2015077382A3 (en) Combined cytology and molecular testing for early detection of esophageal adenocarcinoma
JP2012100636A5 (enExample)
JP2018004657A5 (enExample)
JP7107477B2 (ja) ミトコンドリアtRNA修飾の検出法
JP2016526167A5 (enExample)
JPWO2019117269A1 (ja) 膵がんの検出を補助する方法
RU2018104707A (ru) ИСПОЛЬЗОВАНИЕ МОЛЕКУЛЯРНЫХ МАРКЕРОВ IL-3, IL-33 и IL12ρ40 ДЛЯ ХАРАКТЕРИСТИКИ СТЕПЕНИ ТЯЖЕСТИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ ЧЕЛОВЕКА И МЕТАПНЕВМОВИРУСОМ ЧЕЛОВЕКА
RU2008111496A (ru) Полипептидные маркеры для диагностики рака мочевого пузыря
JP2012524079A5 (enExample)
WO2015188144A3 (en) Fluorescence method for sensing chlorinated disaccharides